Q1 FY27 saw strong financial and operational performance, with revenue at INR 47,364 crore and EBITDA margin at 20%. Capacity utilization and flat product sales hit record highs, while net debt and leverage improved. Steel demand outlook remains robust, though input costs and imports pose risks.Bas…
RNS Number : 8843M Henderson Far East Income Limited 17 July 2026 JANUS HENDERSON FUND MANAGEMENT UK LIMITEDHENDERSON FAR EAST INCOME LIMITEDLEGAL ENTITY IDENTIFIER: 2138008DIQREOD38O59617 July 2026HENDERSON FAR EAST INCOME LIMITED(the 'Company')Issue of EquityThe Company announces that it agre…
RNS Number : 8841M Distribution Finance Cap. Hldgs PLC 17 July 2026 Please note that from 22 March 2021, the Standard TR-1 Form should be completed and submitted to the FCA via our Electronic Submission System (ESS) in relation to notifications of voting rights held in issuers whose shares are…
Revenue and margins declined in Q2 2026 due to higher personnel costs and restructuring, but improved conditions are expected ahead. The divestment of Nethouse boosted liquidity, with a capital return to shareholders planned for 2026.Original document: CombinedX AB [CX] Slides Release — Jul. 17 202…
Core income reached $2.2 billion in Q2 2026, with a 24.9% core ROE and strong underwriting and investment results across all segments. Premiums and book value rose, while over $1.5 billion was returned to shareholders. Innovation and disciplined capital management support a positive outlook.Based o…
Second quarter results featured strong profitability, robust loan and deposit growth driven by the Bank of Houston acquisition, and a stable net interest margin. Leadership transition and a 6% dividend increase were announced, with continued focus on organic growth and operational efficiency.Based…
RNS Number : 8669M Oxford BioDynamics PLC 17 July 2026 TR-1: Standard form for notification of major holdingsThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Uni…
Net sales and profitability surged in Q2 and H1 2026, driven by Nubeqa royalties and Branded Products. Guidance for 2026 was raised, with continued growth expected, while tariffs and operational incidents are not seen as materially disruptive.Based on Orion Oyj Class A [ORNAV] Q2 2026 Audio Transcr…
RNS Number : 8668M Perpetual Limited 17 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING T…
Order intake and revenues returned to organic growth, led by strong performance in umbilicals, medical, industrial heating, and aerospace. Profitability improved, with Kanthal delivering record margins, while market uncertainty persists due to geopolitical and regional challenges.Based on Alleima A…
User base and engagement remain strong, with sequential growth in all revenue streams despite a 21% year-over-year sales decline. Premium and business segments are driving growth, while new funding and the textPlus acquisition enhance financial flexibility and U.S. expansion.Based on Truecaller AB…
Infinity Natural Resources reported a total derivative gain of approximately $57.5 million for the quarter ended June 30, 2026, reflecting $6.4 million of realized losses on settled contracts and about $63.9 million of non‑cash mark‑to‑market unrealized gains on open positions. The company disclose…
Q2 2026: Positive momentum continued in second quarterSTOCKHOLM, July 17, 2026 /PRNewswire/ --Financial highlights Q2 2026$2,803 million net sales, increase of 3.3%1.0% organic sales growth*6.8% operating margin, 9.6% adj. operating margin*$1.35 diluted EPS, 38% decreaseFull year 2026 guidanceAroun…
MEQUON, Wis. and SAN FRANCISCO, July 17, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV:PAIN) ("Vector") and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting…
RNS Number : 8665M Societe Generale SA 17 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING…
RNS Number : 8664M AllianceBernstein LP 17 July 2026 FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the "Code")Public disclosures under Rule 8 of the Code must be made to a Regu…
Net profit grew 17% year-over-year, with strong advances and deposit growth, improved asset quality, and record net interest income. NIMs are expected to remain robust, while fee income softness is seen as temporary. Capital adequacy is high, supporting future growth.Based on South Indian Bank Limi…
Gold Resource Corporation (NYSE American: GORO) (the “Company,” “we,” “our,” or “GRC”) announced that it has received notification from the FTSE Russell that following the Company’s previously announced merger (the “Merger”) with Goldgroup Mining Inc. (“Goldgroup”), the combined company will not be…
RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. NASDAQ:GCTK ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi"), a clinical-stage biopharmaceutical company advancing innovative non-opioid biologic therapies and app…
Q2 2026 saw a 48% revenue increase year-over-year, strong EBITDA and EBIT growth, and a significant improvement in net profit and cash flow. Major orders from NATO customers and the launch of the Ovzon T8 terminal support a robust outlook and expanding market opportunities.Original document: Ovzon…
